Molecular subtyping provides a more precise prognosis and valuable guidance about the best treatment for early-stage breast cancer, according to a presentation by Neil Barth, M.D., at the prestigious Personalized Medicine World Conference (PMWC). Dr. Barth, a medical oncologist and Chief Medical Officer of Agendia, was a featured speaker at the recently concluded conference.
Help employers find you! Check out all the jobs and post your resume.
